Item Type | Name |
Concept
|
Blood Cells
|
Concept
|
Bone Marrow Cells
|
Concept
|
Carcinoma, Squamous Cell
|
Concept
|
Cell Communication
|
Concept
|
Cell Line, Transformed
|
Concept
|
Cell Membrane Permeability
|
Concept
|
Cell Count
|
Concept
|
Cell Differentiation
|
Concept
|
Cell Movement
|
Concept
|
Cell Nucleus
|
Concept
|
Carcinoma, Renal Cell
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Cell Membrane
|
Concept
|
Cell Division
|
Concept
|
Cell Adhesion
|
Concept
|
Cell Cycle
|
Concept
|
Cell Transformation, Neoplastic
|
Concept
|
Epithelial Cells
|
Concept
|
Hematopoietic Stem Cells
|
Concept
|
Neoplastic Cells, Circulating
|
Concept
|
Receptors, Cell Surface
|
Concept
|
Receptors, Antigen, B-Cell
|
Concept
|
Stem Cells
|
Concept
|
CHO Cells
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
Concept
|
Sarcoma, Small Cell
|
Concept
|
Cell Culture Techniques
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Cell Adhesion Molecules
|
Concept
|
3T3 Cells
|
Concept
|
Hematopoietic Cell Growth Factors
|
Concept
|
Cell Transplantation
|
Concept
|
Cell Proliferation
|
Concept
|
Neoplasms, Squamous Cell
|
Concept
|
Jurkat Cells
|
Concept
|
Single-Cell Analysis
|
Concept
|
Carcinoma, Large Cell
|
Concept
|
Carcinoma, Small Cell
|
Concept
|
COS Cells
|
Concept
|
Cell Growth Processes
|
Concept
|
Cell Cycle Proteins
|
Concept
|
Stem Cell Factor
|
Concept
|
Active Transport, Cell Nucleus
|
Concept
|
Platelet Endothelial Cell Adhesion Molecule-1
|
Concept
|
HEK293 Cells
|
Concept
|
Human Umbilical Vein Endothelial Cells
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Small Cell Lung Carcinoma
|
Concept
|
Cell Death
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
Concept
|
Cell Polarity
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
K562 Cells
|
Concept
|
Cell Cycle Checkpoints
|
Concept
|
G1 Phase Cell Cycle Checkpoints
|
Concept
|
Endothelial Cells
|
Concept
|
Programmed Cell Death 1 Receptor
|
Concept
|
Cell Line, Tumor
|
Concept
|
Cell Size
|
Concept
|
Cell Shape
|
Concept
|
Cell Line
|
Concept
|
Cell Physiological Phenomena
|
Concept
|
Cell Survival
|
Concept
|
Cells, Cultured
|
Concept
|
Neoplastic Stem Cells
|
Concept
|
U937 Cells
|
Concept
|
Myeloid Cells
|
Academic Article
|
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
|
Academic Article
|
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
|
Academic Article
|
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL).
|
Academic Article
|
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
|
Academic Article
|
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
|
Academic Article
|
BCR/ABL induces multiple abnormalities of cytoskeletal function.
|
Academic Article
|
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells.
|
Academic Article
|
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
|
Academic Article
|
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
|
Academic Article
|
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
|
Academic Article
|
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
|
Academic Article
|
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.
|
Academic Article
|
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells.
|
Academic Article
|
Hematopoietic growth factors signal through the formation of reactive oxygen species.
|
Academic Article
|
Role of focal adhesion proteins in signal transduction and oncogenesis.
|
Academic Article
|
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL.
|
Academic Article
|
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
Academic Article
|
Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.
|
Academic Article
|
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin.
|
Academic Article
|
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
|
Academic Article
|
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.
|
Academic Article
|
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells.
|
Academic Article
|
Molecular abnormalities in lung cancer.
|
Academic Article
|
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
|
Academic Article
|
Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma.
|
Academic Article
|
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
|
Academic Article
|
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
Academic Article
|
The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo.
|
Academic Article
|
A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion.
|
Academic Article
|
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
|
Academic Article
|
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
|
Academic Article
|
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.
|
Academic Article
|
Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins.
|
Academic Article
|
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
|
Academic Article
|
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration.
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
Academic Article
|
CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance.
|
Academic Article
|
Role of the cytoskeletal protein paxillin in oncogenesis.
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
Academic Article
|
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
Academic Article
|
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
|
Academic Article
|
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases.
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
Academic Article
|
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
|
Academic Article
|
2-methoxyestradiol alters cell motility, migration, and adhesion.
|
Academic Article
|
Molecular alterations in lung cancer. Impact on prognosis.
|
Academic Article
|
Small cell lung cancer: from molecular biology to novel therapeutics.
|
Academic Article
|
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
Academic Article
|
Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate.
|
Academic Article
|
p53 and Bcl-2 in small cell-lung cancer.
|
Academic Article
|
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system.
|
Academic Article
|
Phase II study of imatinib in patients with small cell lung cancer.
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
Academic Article
|
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
Academic Article
|
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
|
Academic Article
|
Molecular biology of malignant mesothelioma: a review.
|
Academic Article
|
A review of topoisomerase inhibition in lung cancer.
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
Academic Article
|
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors.
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
Academic Article
|
MET as a target for treatment of chest tumors.
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
Academic Article
|
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
Academic Article
|
Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.
|
Academic Article
|
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.
|
Academic Article
|
The role of ephrins and Eph receptors in cancer.
|
Academic Article
|
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
Academic Article
|
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
Academic Article
|
The role of chemokine receptor CXCR4 in lung cancer.
|
Academic Article
|
Fyn: a novel molecular target in cancer.
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
Academic Article
|
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
|
Academic Article
|
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
Academic Article
|
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.
|
Academic Article
|
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
Academic Article
|
Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma.
|
Academic Article
|
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer.
|
Academic Article
|
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
|
Academic Article
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
Academic Article
|
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.
|
Academic Article
|
Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
Academic Article
|
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
Academic Article
|
Mind-mapping for lung cancer: towards a personalized therapeutics approach.
|
Academic Article
|
PAX3 and SOX10 activate MET receptor expression in melanoma.
|
Academic Article
|
The effects of monensin on membrane lipids of cultured human skin fibroblasts.
|
Academic Article
|
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
|
Academic Article
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
Academic Article
|
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer.
|
Academic Article
|
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
|
Academic Article
|
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
Academic Article
|
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Academic Article
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
Academic Article
|
Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report.
|
Academic Article
|
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
Academic Article
|
CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
|
Academic Article
|
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
Academic Article
|
Altered membrane fluidity in rat hepatocytes during endotoxic shock.
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
Academic Article
|
MET molecular mechanisms and therapies in lung cancer.
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
Academic Article
|
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
|
Academic Article
|
Personalized treatment of lung cancer.
|
Academic Article
|
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
Academic Article
|
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
Academic Article
|
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).
|
Academic Article
|
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
|
Academic Article
|
Involvement of the adapter protein CRKL in integrin-mediated adhesion.
|
Academic Article
|
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
|
Academic Article
|
Detection and analysis of lung cancer cells from body fluids using a rare event imaging system.
|
Academic Article
|
Molecular and cellular biology of small cell lung cancer.
|
Academic Article
|
Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung.
|
Academic Article
|
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
Academic Article
|
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
|
Academic Article
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
Academic Article
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
Academic Article
|
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
|
Academic Article
|
Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of proteins to lysosomes is not irreversible.
|
Academic Article
|
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
|
Academic Article
|
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
|
Academic Article
|
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
Academic Article
|
Evidence-based role of bevacizumab in non-small cell lung cancer.
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
Academic Article
|
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
|
Academic Article
|
Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases.
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
Academic Article
|
EphB4 as a therapeutic target in mesothelioma.
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
Academic Article
|
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
|
Academic Article
|
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
|
Academic Article
|
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
|
Academic Article
|
Increased µ-opioid receptor expression in metastatic lung cancer.
|
Academic Article
|
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
Academic Article
|
Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells.
|
Academic Article
|
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
Academic Article
|
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
Academic Article
|
Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
Academic Article
|
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
Academic Article
|
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
|
Academic Article
|
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
Academic Article
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
Academic Article
|
Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
Academic Article
|
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
A new PET/CT volumetric prognostic index for non-small cell lung cancer.
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
Academic Article
|
Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin.
|
Academic Article
|
PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
Academic Article
|
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
Academic Article
|
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.
|
Academic Article
|
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
|
Academic Article
|
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
|
Academic Article
|
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
Academic Article
|
1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
Academic Article
|
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
|
Academic Article
|
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
Academic Article
|
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
Academic Article
|
DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER.
|
Academic Article
|
KRAS in Non-Small-Cell Lung Cancer-Reply.
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
Academic Article
|
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
|
Academic Article
|
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
|
Academic Article
|
A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer.
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
Academic Article
|
CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).
|
Academic Article
|
Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC).
|
Academic Article
|
A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naïve advanced non-small cell lung cancer (NSCLC).
|
Academic Article
|
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
|
Academic Article
|
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
|
Academic Article
|
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
Academic Article
|
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
|
Academic Article
|
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
Academic Article
|
Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
|
Academic Article
|
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.
|
Academic Article
|
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
|
Academic Article
|
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
Academic Article
|
Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
|
Academic Article
|
Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.
|
Academic Article
|
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
|
Academic Article
|
Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.
|
Academic Article
|
Managing Patients With Relapsed Small-Cell Lung Cancer.
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
Academic Article
|
Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.
|
Academic Article
|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
|
Academic Article
|
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
|
Academic Article
|
State-of-the-art considerations in small cell lung cancer brain metastases.
|
Academic Article
|
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
|
Academic Article
|
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
Academic Article
|
The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.
|
Academic Article
|
RLIP inhibition suppresses breast-to-lung metastasis.
|
Academic Article
|
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
|
Academic Article
|
RLIP: An existential requirement for breast carcinogenesis.
|
Academic Article
|
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
|
Academic Article
|
Early mortality of stage IV non-small cell lung cancer in the United States.
|
Academic Article
|
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
|
Academic Article
|
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
|
Academic Article
|
Targeted Therapies in Non-small-Cell Lung Cancer.
|
Academic Article
|
Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.
|
Academic Article
|
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.
|
Academic Article
|
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
|
Academic Article
|
Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells.
|
Academic Article
|
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS.
|
Academic Article
|
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
|
Academic Article
|
RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis.
|
Academic Article
|
SOX9: The master regulator of cell fate in breast cancer.
|
Academic Article
|
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
Academic Article
|
Therapeutic targeting of miRNA-216b in cancer.
|
Academic Article
|
Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach.
|
Academic Article
|
Targeting RLIP with CRISPR/Cas9 controls tumor growth.
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
Academic Article
|
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
|
Academic Article
|
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
|
Academic Article
|
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
|
Academic Article
|
Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.
|
Academic Article
|
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?
|
Academic Article
|
Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics.
|
Academic Article
|
Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.
|
Academic Article
|
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
|
Academic Article
|
Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas.
|
Academic Article
|
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease.
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
Academic Article
|
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
Academic Article
|
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
Academic Article
|
RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
Academic Article
|
Quantifying Cancer: More Than Just a Numbers Game.
|
Academic Article
|
Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey.
|
Academic Article
|
Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
|
Academic Article
|
Disparate outcomes in nonsmall cell lung cancer by immigration status.
|
Academic Article
|
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer.
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin ß-Like 1-ß-Catenin Protein Complex.
|
Academic Article
|
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
|
Academic Article
|
MicroRNA-1: Diverse role of a small player in multiple cancers.
|
Academic Article
|
The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer.
|
Academic Article
|
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
Academic Article
|
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.
|
Academic Article
|
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
|
Academic Article
|
Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer.
|
Academic Article
|
Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
|
Academic Article
|
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
|
Academic Article
|
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
|
Academic Article
|
The next targets for small cell lung cancer.
|
Academic Article
|
Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.
|
Academic Article
|
Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
|
Academic Article
|
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
Academic Article
|
Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
Academic Article
|
Report of the First International Symposium on NUT Carcinoma.
|
Academic Article
|
Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer.
|
Academic Article
|
Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics.
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|
Academic Article
|
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
|
Academic Article
|
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
|
Academic Article
|
Integration of artificial intelligence in lung cancer: Rise of the machine.
|
Academic Article
|
Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma.
|
Academic Article
|
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
|
Academic Article
|
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.
|
Concept
|
Cell Self Renewal
|
Concept
|
A549 Cells
|
Concept
|
Cell Surface Display Techniques
|
Concept
|
MCF-7 Cells
|
Grant
|
ABNORMALITIES OF MOTILITY OF CML CELLS
|
Grant
|
Role of Paxillin in Lung Cancer
|
Grant
|
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|
Academic Article
|
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
|
Academic Article
|
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
|
Academic Article
|
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
|
Academic Article
|
LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancer.
|
Academic Article
|
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.
|
Academic Article
|
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
|
Academic Article
|
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.
|
Academic Article
|
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
|
Academic Article
|
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
|
Academic Article
|
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP.
|